PMC10388547_01
MRI of the patient's meningioma in October 2022 and January 2023.
fonc-13-1192575-g001.jpg
PMC10388547_01_fonc-13-1192575-g001.jpg
f1
An MRI revealed space-occupying lesions in the left parietal lobe underneath the cranial plate (Figure 1). After two treatment cycles, the patient's clinical symptoms were significantly relieved, and the imaging assessment confirmed a stable disease (Figures 1, 2).
CT of the patient's chest and abdomen in October 2022 and January 2023.
fonc-13-1192575-g002.jpg
PMC10388547_01_fonc-13-1192575-g002.jpg
f2
A computed tomography (CT) scan revealed several enlarged lymph nodes in the left lower lung area, retroperitoneum, and abdominopelvic region, as well as soft tissue mass-like lesions under the capsule of the right lobe of the liver (Figure 2). After two treatment cycles, the patient's clinical symptoms were significantly relieved, and the imaging assessment confirmed a stable disease (Figures 1, 2).
Hematoxylin & eosin stain of tumor biopsy specimens in 2022.
fonc-13-1192575-g003.jpg
PMC10388547_01_fonc-13-1192575-g003.jpg
f3
And there were more than 4 mitotic figures per 10 high power fields and sheets of tumor cell necrosis (Figure 3).
Immunohistochemistry of tumor biopsy specimens in 2022. CD56(+), EMA(+), Vimentin(+).
fonc-13-1192575-g004.jpg
PMC10388547_01_fonc-13-1192575-g004.jpg
f4
The pathological specimens tested positive for CD56, Vimentin, Desmin, S-100, EMA but were negative for CK, CD34, NSE, PR, MelanA, alpha-inhibin, and PD-1(Figure 4).